Theken Companies Acquire VisionAir Solutions to Enhance Patient Care | The Healthcare Technology Report.
Summary
This strategic move marks a significant step forward in advancing patient care and improving the quality of life for those suffering from central airway obstruction (CAO). The impact of VisionAirs technology extends to a broad range of patients, including those as young as 22 years old suffering from symptomatic central airway obstruction. These 3D stents can be placed anywhere within the airway accessible by a rigid bronchoscope, offering a level of adaptability and precision previously unattainable with conventional silicone Y-stents that come in standard sizes and dimensions. The Cleveland Clinic, which originally owned VisionAir Solutions, will continue to receive royalty payments and commercialization revenues for its pioneering technology. Notably, VisionAir will continue to develop and produce the stents, with Dr. Gildea and other Cleveland Clinic inventors entitled to royalty payments and commercialization earnings.